Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Standard
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. / Malard, Florent; Kröger, Nicolaus; Gabriel, Ian H; Hübel, Kai; Apperley, Jane F; Basak, Grzegorz W; Douglas, Kenneth W; Geraldes, Catarina; Jaksic, Ozren; Koristek, Zdenek; Lanza, Francesco; Lemoli, Roberto; Mikala, Gabor; Selleslag, Dominik; Worel, Nina; Mohty, Mohamad; Duarte, Rafael F.
In: BIOL BLOOD MARROW TR, Vol. 18, No. 2, 2, 2012, p. 314-317.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
AU - Malard, Florent
AU - Kröger, Nicolaus
AU - Gabriel, Ian H
AU - Hübel, Kai
AU - Apperley, Jane F
AU - Basak, Grzegorz W
AU - Douglas, Kenneth W
AU - Geraldes, Catarina
AU - Jaksic, Ozren
AU - Koristek, Zdenek
AU - Lanza, Francesco
AU - Lemoli, Roberto
AU - Mikala, Gabor
AU - Selleslag, Dominik
AU - Worel, Nina
AU - Mohty, Mohamad
AU - Duarte, Rafael F
PY - 2012
Y1 - 2012
N2 - Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), respectively. Data suggests that fludarabine and lenalidomide therapy may have a deleterious effect on stem cell mobilization. In the European compassionate use program, 48 patients (median age 57 years) previously treated with fludarabine (median 5 cycles; range: 1-7 cycles) were given plerixafor plus granulocyte colony-stimulating factor (G-CSF) for remobilization following a primary mobilization attempt. The overall median number of CD34+ cells collected was 2.3 × 10(6)/kg (range: 0.3-13.4). The minimum required number of CD34+ cells (?2.0 × 10(6)/kg) was collected from 58% of patients in a median of 2 days. Thirty-five patients (median age = 57 years) previously treated with lenalidomide (median 5 cycles; range: 1-10 cycles) were given plerixafor plus G-CSF for remobilization. The overall median number of CD34+ cells collected was 3.4 × 10(6)/kg (range: 1.1-14.8). The minimum required number of CD34+ cells (?2.0 × 10(6) per kg) was collected from 69% of patients in a median of 2 days. In conclusion, salvage mobilization with plerixafor plus G-CSF is successful in the majority of patients with MM previously treated with lenalidomide. In fludarabine-exposed patients, only 58% of patients will achieve successful salvage mobilization with plerixafor plus G-CSF, suggesting the need for novel mobilization regimens algorithms in this subgroup of patients.
AB - Fludarabine and lenalidomide are essential drugs in the front-line treatment of non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), respectively. Data suggests that fludarabine and lenalidomide therapy may have a deleterious effect on stem cell mobilization. In the European compassionate use program, 48 patients (median age 57 years) previously treated with fludarabine (median 5 cycles; range: 1-7 cycles) were given plerixafor plus granulocyte colony-stimulating factor (G-CSF) for remobilization following a primary mobilization attempt. The overall median number of CD34+ cells collected was 2.3 × 10(6)/kg (range: 0.3-13.4). The minimum required number of CD34+ cells (?2.0 × 10(6)/kg) was collected from 58% of patients in a median of 2 days. Thirty-five patients (median age = 57 years) previously treated with lenalidomide (median 5 cycles; range: 1-10 cycles) were given plerixafor plus G-CSF for remobilization. The overall median number of CD34+ cells collected was 3.4 × 10(6)/kg (range: 1.1-14.8). The minimum required number of CD34+ cells (?2.0 × 10(6) per kg) was collected from 69% of patients in a median of 2 days. In conclusion, salvage mobilization with plerixafor plus G-CSF is successful in the majority of patients with MM previously treated with lenalidomide. In fludarabine-exposed patients, only 58% of patients will achieve successful salvage mobilization with plerixafor plus G-CSF, suggesting the need for novel mobilization regimens algorithms in this subgroup of patients.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Time Factors
KW - Transplantation, Autologous
KW - Antineoplastic Agents/administration & dosage/adverse effects
KW - Anti-HIV Agents/administration & dosage/adverse effects
KW - Antigens, CD34/blood
KW - Granulocyte Colony-Stimulating Factor/administration & dosage/adverse effects
KW - Hematopoietic Stem Cell Mobilization/methods
KW - Heterocyclic Compounds/administration & dosage/adverse effects
KW - Lymphoma, Non-Hodgkin/blood/therapy
KW - Multiple Myeloma/blood/therapy
KW - Peripheral Blood Stem Cell Transplantation
KW - Thalidomide/administration & dosage/adverse effects/analogs & derivatives
KW - Vidarabine/administration & dosage/adverse effects/analogs & derivatives
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Time Factors
KW - Transplantation, Autologous
KW - Antineoplastic Agents/administration & dosage/adverse effects
KW - Anti-HIV Agents/administration & dosage/adverse effects
KW - Antigens, CD34/blood
KW - Granulocyte Colony-Stimulating Factor/administration & dosage/adverse effects
KW - Hematopoietic Stem Cell Mobilization/methods
KW - Heterocyclic Compounds/administration & dosage/adverse effects
KW - Lymphoma, Non-Hodgkin/blood/therapy
KW - Multiple Myeloma/blood/therapy
KW - Peripheral Blood Stem Cell Transplantation
KW - Thalidomide/administration & dosage/adverse effects/analogs & derivatives
KW - Vidarabine/administration & dosage/adverse effects/analogs & derivatives
M3 - SCORING: Journal article
VL - 18
SP - 314
EP - 317
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 2
M1 - 2
ER -
